Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple MyelomaGlobeNewsWire • 12/07/23
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IOGlobeNewsWire • 12/07/23
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology PortfolioGlobeNewsWire • 11/30/23
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)Seeking Alpha • 11/28/23
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future SalesInvestors Business Daily • 11/27/23
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseGlobeNewsWire • 11/27/23
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference (Transcript)Seeking Alpha • 11/15/23
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)GlobeNewsWire • 11/13/23
Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo® (cemiplimab) in Patients with Cutaneous Squamous Cell CarcinomaBusiness Wire • 11/13/23
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)Seeking Alpha • 11/11/23
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASHGlobeNewsWire • 11/03/23